Search

Muromonab

More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. … Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).

PRX-07034

Latiglutenase

Thiacloprid

Bioymifi

Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent. … Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic.

Irofulven

A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track … MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis.

C31G

in a phase III pivotal clinical trial for the reduction of sexual transmission of human immunodeficiency virus (HIV). … C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment

Tezampanel

Tezampanel is an AMPA receptor antagonist.

Nomifensine

FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). … The approved application holder removed Merital capsules from the market on January 23, 1986.

Moexiprilat

The active metabolite of the prodrug Moexipril.